Company profile

WBA stock data

(
)

Calendar

9 Jul 20
11 Jul 20
31 Aug 20

News

Company financial data Financial data

Quarter (USD) May 20 Feb 20 Nov 19 Aug 19
Revenue 34.63B 35.82B 34.34B 33.95B
Net income -1.73B 952M 842M 687M
Diluted EPS 0.75
Net profit margin -4.98% 2.66% 2.45% 2.02%
Operating income -1.58B 1.23B 1.01B 878M
Net change in cash -24M -19M -212M 255M
Cash on hand 768M 792M 811M 1.02B
Cost of revenue 28.19B 28.31B 27.08B 26.73B
Annual (USD) Aug 19 Aug 18 Aug 17 Aug 16
Revenue 136.87B 131.54B 118.21B 117.35B
Net income 3.96B 5.03B 4.1B 4.19B
Diluted EPS 4.31 5.05 3.78 3.82
Net profit margin 2.89% 3.82% 3.47% 3.57%
Operating income 5B 6.29B 5.48B 6B
Net change in cash 238M -2.52B -6.51B 6.81B
Cash on hand 1.02B 785M 3.3B 9.81B
Cost of revenue 106.79B 100.75B 89.05B 87.48B

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
8 Jul 20 Brailer David J Phantom Stock Units Common Stock Grant Aquire A No 42.29 709.388 30K 43,972.7
8 Jul 20 Lederer John Anthony Phantom Stock Units Common Stock Grant Aquire A No 42.29 591.156 25K 21,761.1
8 Jul 20 Murphy Dominic Phantom Stock Units Common Stock Grant Aquire A No 42.29 591.156 25K 31,466.4
1 Jun 20 Kehoe James Common Stock Payment of exercise Dispose F No 43.3 7,777 336.74K 108,059
22 Apr 20 Lederer John Anthony Phantom Stock Units Common Stock Grant Aquire A No 43.31 577.234 25K 20,938.6
57.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1236 1309 -5.6%
Opened positions 115 176 -34.7%
Closed positions 188 103 +82.5%
Increased positions 430 360 +19.4%
Reduced positions 538 594 -9.4%
13F shares
Current Prev Q Change
Total value 253.93B 312.63B -18.8%
Total shares 500.87M 523.61M -4.3%
Total puts 7.23M 9.06M -20.2%
Total calls 6.66M 7.26M -8.2%
Total put/call ratio 1.1 1.2 -13.1%
Largest owners
Shares Value Change
Vanguard 71.4M $3.27B +2.8%
BLK BlackRock 50.29M $2.3B -3.7%
STT State Street 46.68M $2.14B +0.0%
BEN Franklin Resources 17.49M $800.27M -4.3%
Caisse De Depot Et Placement Du Quebec 14.82M $677.95M +2.3%
FMR 12.31M $563.13M +21.9%
Geode Capital Management 11.48M $524.18M +2.4%
NTRS Northern Trust 9.96M $455.85M -3.3%
LSV Asset Management 9.68M $442.8M -6.2%
JPM JPMorgan Chase & Co. 9.04M $413.57M +17.6%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -8.36M EXIT
Capital International Investors 1.44M -3.56M -71.1%
Aristotle Capital Management 7.29M +2.53M +53.2%
FMR 12.31M +2.21M +21.9%
Burgundy Asset Management 5.03M -2.03M -28.7%
Vanguard 71.4M +1.94M +2.8%
BLK BlackRock 50.29M -1.94M -3.7%
Two Sigma Advisers 1.83M -1.78M -49.3%
GS The Goldman Sachs Group, Inc. 6.74M -1.59M -19.1%
Thornburg Investment Management 6.44M +1.46M +29.2%

Financial report summary

?
Competition
Cigna
Risks
  • Reductions in third-party reimbursement levels, from private or governmental agency plans, and potential changes in industry pricing benchmarks for prescription drugs could materially and adversely affect our results of operations.
  • A shift in pharmacy mix toward lower margin plans, products, and programs could adversely affect our results of operations.
  • We derive a significant portion of our sales in the United States from prescription drug sales reimbursed by a limited number of pharmacy benefit management companies.
  • We could be adversely affected by a decrease in the introduction of new brand name and generic prescription drugs as well as increases in the cost to procure prescription drugs.
  • Consolidation and strategic alliances in the healthcare industry could adversely affect our business operations, competitive positioning, financial condition and results of operations.
  • Our growth strategy is partially dependent upon our ability to identify and successfully complete acquisitions, joint ventures and other strategic partnerships and alliances.
  • We are exposed to risks related to litigation and other legal proceedings.
  • Our business results depend on our ability to successfully manage ongoing organizational change and business transformation and achieve cost savings and operating efficiency initiatives.
  • The industries in which we operate are highly competitive and constantly evolving. New entrants to the market, existing competitor actions or other changes in market dynamics could adversely impact us.
  • Our substantial international business operations subject us to a number of operating, economic, political, regulatory and other international business risks.
  • We are exposed to risks associated with foreign currency exchange rate fluctuations.
  • We may experience a significant disruption in our information technology and computer systems.
  • If we or the businesses we interact with do not maintain the privacy and security of sensitive customer and business information, it could damage our reputation and we could suffer a loss of revenue, incur substantial additional costs and become subject to litigation and regulatory scrutiny.
  • A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on our reputation and profitability.
  • We could be adversely affected by violations of anti-bribery, anti-corruption and/or international trade laws.
  • Disruption in our global supply chain could negatively impact our businesses.
  • We use a single wholesaler of branded and generic pharmaceutical drugs as our primary source of such products for our Retail Pharmacy USA division.
  • The anticipated strategic and financial benefits of our relationship with AmerisourceBergen may not be realized.
  • We may not realize the anticipated benefits of the acquisition of assets from Rite Aid, which could adversely impact our results of operations.
  • From time to time, we make investments in companies over which we do not have sole control. Some of these companies may operate in sectors that differ from our current operations and have different risks.
  • Changes in economic conditions could adversely affect consumer buying practices.
  • Economic conditions in Europe and certain emerging market countries, together with austerity measures being taken by certain governments, could adversely affect us.
  • If we do not successfully develop and maintain a relevant omni-channel experience for our customers, our businesses and results of operations could be adversely impacted.
  • If the merchandise and services that we offer fail to meet customer needs, our sales may be adversely affected.
  • Our private brand offerings expose us to various additional risks.
  • We face significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to our success, and failure to do so could have an adverse impact on our future performance.
  • We are subject to payment-related and other financial services risks that could increase our operating costs, expose us to fraud or theft, subject us to potential liability and potentially disrupt our business operations.
  • Changes in healthcare regulatory environments may adversely affect our businesses.
  • We could be adversely affected by product liability, product recall, personal injury or other health and safety issues.
  • We have significant outstanding debt; our debt and associated payment obligations could significantly increase in the future if we incur additional debt and do not retire existing debt.
  • We could be adversely affected by downgrades to our credit ratings or disruptions in our ability to access well-functioning capital markets.
  • We may be unable to keep existing store locations or open new locations in desirable places on favorable terms, which could materially and adversely affect our results of operations.
  • As a holding company, Walgreens Boots Alliance is dependent on funding from its operating subsidiaries to pay dividends and other obligations.
  • Our quarterly results may fluctuate significantly.
  • Our businesses are seasonal in nature, and adverse events during the holiday and cough, cold and flu seasons could adversely impact our operating results.
  • We could be adversely impacted by changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters.
  • We have a substantial amount of goodwill and other intangible assets which could, in the future, become impaired and result in material non-cash charges to our results of operations.
  • We could be subject to adverse changes in tax laws, regulations and interpretations or challenges to our tax positions.
  • Our insurance strategies may expose us to unexpected costs.
  • We could be adversely impacted by changes in assumptions used in calculating pension assets and liabilities.
  • Certain stockholders may have significant voting influence over matters requiring stockholder approval.
  • Conflicts of interest, or the appearance of conflicts of interest, may arise because certain of our directors and officers are also owners or directors of companies we may have dealings with.
  • Our certificate of incorporation and bylaws, Delaware law and/or our agreements with certain stockholders may impede the ability of our stockholders to make changes to our Board or impede a takeover.
  • We cannot guarantee that our stock repurchase program will be fully implemented or that it will enhance long-term stockholder value.
  • The market price of our common stock may be volatile.
  • There are a number of additional business risks that could materially and adversely affect our businesses and financial results.
Management Discussion
  • This division comprises the retail pharmacy business operating in the United States.
  • 1See “--Non-GAAP Measures” below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures.
  • 2Includes immunizations.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accommodate, aftermath, ahead, airport, Alex, alter, amplified, automating, behavior, Bilateral, bond, catastrophic, certainty, Club, Committee, compel, compete, convention, copy, cyber, deferral, deficiency, disease, doctor, DOJ, domestic, effort, England, entry, EPS, essential, establishing, Exhibit, external, fail, FCA, food, foregoing, fragrance, furloughing, Gourlay, grocery, guarantor, harm, healthy, high, hospital, Internet, judgment, labor, largest, Leadership, leveraging, lockdown, looting, macroeconomic, manual, marketplace, mask, medical, navigating, obsolete, online, outsource, owed, pace, partly, patient, pay, peak, peer, photo, pretax, prevalence, proactive, proceed, published, quickly, recessionary, recovery, serve, shift, shifted, shopping, shortened, slowdown, station, stemming, street, sum, suspended, suspending, syndicated, temporarily, temporary, terrorism, tradename, transmission, transportation, underwriting, undrawn, unemployment, unimpeded, unprecedented, vandalism, Village, VillageMD, wage, war, wave, WBAFSL, withdrew, York
Removed: ago, assumed, clearance, Collaborative, determinable, disclose, discrete, ending, highly, proposed, readily, requirement

Patents

APP
Utility
Kit of Cosmetic Skincare Compositions
5 Mar 20
According to the present invention there is provided a kit of cosmetic compositions, the kit comprising: 1) a cleansing composition, the cleansing composition comprising: (i) a cosmetically acceptable carrier; (ii) one or more surfactants; (iii) one or more anti-inflammatory agent; (iv) one or more antioxidant agent selected from polyphenolic antioxidant agents and antioxidant vitamins; (v) one or more skin-soothing agent; 2) a skin balancing composition, the skin balancing composition comprising: (i) a cosmetically acceptable carrier; (ii) Ophiopogon japonicas extract; (iii) one or more antioxidant agent selected from polyphenolic antioxidant agents and antioxidant vitamins; (iv) one or more sebum control agent selected from Rosa canina extract and sphingosine compounds; 3) a daytime protective composition, the daytime protective composition comprising: (i) a cosmetically acceptable carrier; (ii) one or more UV-filter; (iii) one or more antioxidant agent selected from polyphenolic antioxidant agents and antioxidant vitamins; (iv) one or more skin-soothing agent; and 4) an overnight treatment composition, the overnight treatment composition comprising: (i) a cosmetically acceptable carrier; (ii) one or more polyphenolic antioxidant agent; (iii) one or more antioxidant vitamin; (iv) one or more skin-soothing agent.
APP
Utility
Cosmetic Skincare Compositions
5 Mar 20
According to the present invention there is provided a cosmetic composition comprising: (i) a polyphenolic antioxidant agent; and (ii) a sphingosine compound.
APP
Utility
Skin Care Composition and Method Thereof
31 Oct 19
The disclosed technology relates to a composition comprising: 0.1 to 3 wt % (or 0.5 to 2.5 wt %) of a beta hydroxy acid, 0.05 to 3 wt % (or 0.09 to 2.5 wt %) of an O-substituted ascorbic acid or a derivative thereof, and a cosmetically acceptable medium comprising an aqueous phase, wherein a beta hydroxy acid is present at a higher concentration than O-substituted ascorbic acid or a derivative thereof.